Neuromethods,
Год журнала:
2023,
Номер
unknown, С. 3 - 47
Опубликована: Янв. 1, 2023
Alzheimer's
disease
(AD)
is
a
neurological
ailment
that
affects
older
people
and
causes
steady
decline
in
their
cognitive
function.
The
impairments
found
are
presumed
to
be
the
result
of
synapse
disruption
neurochemical
deficits.
Several
abnormalities
have
been
throughout
progressive
aging,
these
connected
dysfunction
seen
sporadic
stage
AD.
There
various
hypotheses
explaining
AD,
such
as
aberrant
deposits
amyloid
β
(Aβ)
protein
extracellular
spaces
neurons,
production
twisted
fibers
tau
proteins
inside
cholinergic
neuron
damage,
inflammation,
oxidative
stress,
so
on,
many
anti-AD
therapeutics
developed
based
on
hypotheses.
While
current
pharmacological
treatments
assist
relieving
symptoms
AD
enhance
patient's
quality
life,
they
do
not
halt
or
cure
disease.
Presently,
targeted
drug
delivery
central
nervous
system
(CNS)
for
therapy
hampered
by
difficulties
posed
blood-brain
interfaces
surrounding
CNS,
reducing
therapeutic
bioavailability.
Among
innovative
ways
overcome
restrictions
successfully
deliver
pharmaceuticals
nanoparticles
(NPs)
can
barriers,
offering
new
strategies
terms
dealing
drugs
cross
barrier
(BBB)
enter
brain
more
adequately.
Various
options
treatment
shown
promising
results
preclinical
research
currently
being
tested
clinical
trials
last
decade.
In
addition
generating
chemical
entities,
natural
compounds
alkaloids,
terpenoids,
flavonoids,
curcumin
isolated
evaluated
all
demonstrated
actions
against
range
targets.
Moreover,
computational
techniques
also
proven
quite
useful
time
money
when
developing
therapies.
Molecular
modeling,
virtual
screening,
docking
widely
used
researchers
worldwide
recent
years.
These
already
aided
development
several
compounds.
purpose
this
chapter
summarize
highlight
advancements
novel
therapies
implications
Biophysical Chemistry,
Год журнала:
2025,
Номер
unknown, С. 107441 - 107441
Опубликована: Март 1, 2025
Amyloid
peptide
non-fibrillar
oligomers
cause
neurotoxicity
and
may
contribute
to
Alzheimer's
disease
(AD)
pathogenesis.
Mounting
evidence
indicates
that
Aβ1-42
disrupt
remodel
neuronal
membrane,
causing
cell
death.
The
involvement
of
individual
membrane
constituents
in
real-time
aggregate
assembly
is
unclear
due
complexity
membrane.
We
used
non-Faradaic
electrochemical
impedance
spectroscopy
(EIS)
track
monomeric
binding
aggregation
pathways
asymmetric
micropore
suspended
lipid
bilayer
membranes
with
anionic
phospholipids
glycosphingolipids.
Anionic
DOPC:PIP2
pore
showed
pore-formation
within
2
h
incubation,
but
insertion
occurred
over
6
h,
an
onset
time
∼6-8
for
at
the
surface.
Among
different
gangliosides,
GM1-
GM3-containing
did
not
result
development,
receptor
mediated
formation
caused
admittance
decrease
h.
In
contrast,
partial
surface
increases
GD1a
mixed
GSL
membranes,
arresting
aggregation.
Time-lapsed
AFM
imaging
solid
supported
bilayers
(aSLBs)
corroborated
EIS
findings,
capturing
routes.
Fluorescence
lifetime
(FLIM)
spatial
resolved
single-point
fluorescence
correlation
(FCS)
aSLBs
revealed
membrane-peptide
interaction,
assembly,
induced
reorganization.
Treatment
antidepressants
fluoxetine
imipramine
therapeutics,
synergy,
which
are
cost-effective
capable
crossing
central
nervous
system
(CNS+),
resulted
disassembly
aggregates,
fibrils.
Overall,
data
suggests
membrane-mediated
correct
timing
AD
progression
halt
or
reverse
amyloid
through
use
repurposed
drugs.
Biomolecules,
Год журнала:
2025,
Номер
15(4), С. 592 - 592
Опубликована: Апрель 16, 2025
Serotonin
5HT1A
receptors
may
be
affected
in
neurodegeneration,
such
as
Alzheimer’s
disease
(AD)
and
Parkinson’s
(PD).
Using
the
selective
receptor
positron
emission
tomography
(PET)
imaging
agent,
[18F]mefway,
autoradiographic
studies
from
postmortem
human
brains
of
AD,
PD,
cognitively
normal
(CN)
subjects
were
carried
out.
Levels
[18F]mefway
binding
compared
with
monoamine
oxidase
A
(MAO-A)
measured
using
[18F]FAZIN3
dopamine
D2/D3
[18F]fallypride
same
subjects.
Autoradiograms
brain
sections
anterior
cingulate
corpus
callosum
CN,
AD
(n
=
6
each
group)
analyzed.
Significant
increased
was
found
(+30%)
PD
(+11%)
to
CN
brains.
This
increase
positively
correlated
binding,
suggesting
greater
availability
when
MAO-A
levels
are
higher.
Differences
three
groups
not
significant.
Our
results
support
finding
that
is
elevated
cortex
negatively
MAO-A.
upregulation
potentially
a
response
lower
serotonin
due
activity
this
region
or
other
neuroinflammatory
changes.
Thus,
potential
target
for
diagnostic
therapeutic
approaches
PD.
Biology,
Год журнала:
2022,
Номер
11(12), С. 1822 - 1822
Опубликована: Дек. 14, 2022
Alzheimer's
disease
(AD),
which
is
characterized
by
extracellular
accumulation
of
amyloid-beta
peptide
and
intracellular
aggregation
hyperphosphorylated
tau,
the
most
common
form
dementia.
Memory
loss,
cognitive
decline
disorientation
are
ultimate
consequences
neuronal
death,
synapse
loss
neuroinflammation
in
AD.
In
general,
there
many
brain
regions
affected
but
locus
coeruleus
(LC)
one
earliest
indicators
neurodegeneration
Since
LC
main
source
noradrenaline
(NA)
brain,
degeneration
AD
leads
to
decreased
NA
levels,
causing
increased
neuroinflammation,
enhanced
amyloid
tau
burden,
phagocytosis
impairment
cognition
long-term
synaptic
plasticity.
this
review,
we
summarized
current
findings
on
coeruleus-noradrenaline
system
its
dysfunction
now
recognized
as
an
important
contributor
progression.
Basic & Clinical Pharmacology & Toxicology,
Год журнала:
2024,
Номер
135(3), С. 237 - 249
Опубликована: Июль 17, 2024
Abstract
Alzheimer's
disease
is
characterized
by
progressive
cognitive
decline,
and
behavioural
psychological
symptoms
of
dementia
are
common.
The
APOE
ε4
allele,
a
genetic
risk
factor,
significantly
increases
susceptibility
to
the
disease.
Despite
efforts
effectively
treat
disease,
only
seven
drugs
approved
for
its
treatment,
two
these
prevent
progression.
This
highlights
need
identify
new
pharmacological
options.
review
focuses
on
mimetic
peptides,
small
molecule
correctors
HAE‐4
antibodies
that
target
ApoE.
These
reduce
β‐amyloid‐induced
neurodegeneration
in
preclinical
models.
In
addition,
loop
diuretics
such
as
bumetanide
furosemide
show
potential
prevalence
humans,
antidepressants
imipramine
improve
function
individuals
diagnosed
with
Consistent
this,
both
classes
have
been
shown
exert
neuroprotective
effects
inhibiting
ApoE4‐catalysed
Aβ
aggregation
Moreover,
peroxisome
proliferator‐activated
receptor
ligands,
particularly
pioglitazone
rosiglitazone,
ApoE4‐induced
animal
However,
they
do
not
decline
allele
carriers.
Finally,
ApoE4
impairs
integrity
blood–brain
barrier
haemostasis.
On
this
basis,
modulation
promising
avenue
treatment
late‐onset
International Journal of Molecular Sciences,
Год журнала:
2022,
Номер
23(9), С. 4942 - 4942
Опубликована: Апрель 29, 2022
Depression
is
a
very
prevalent
and
complex
disease.
This
condition
associated
with
high
rate
of
relapse,
making
its
treatment
challenge.
Thus,
an
intensive
investigation
this
disease
necessary.
In
work,
through
cell
viability
assays
(MTT
neutral
red
assays)
alkaline
comet
assays,
we
aimed
to
test
the
induction
stress
in
human
SH-SY5Y
cells
application
hydrocortisone
hydrogen
peroxide
reversal
or
attenuation
mirtazapine
cells.
Our
results
demonstrated
that
peroxide,
not
hydrocortisone,
can
induce
cellular
stress,
as
evidenced
by
DNA
damage
global
reduction,
which
were
alleviated
antidepressant
mirtazapine.
The
establishment
model
depression
important
study
new
possibilities
using
cultures.
Alzheimer s Research & Therapy,
Год журнала:
2023,
Номер
15(1)
Опубликована: Июль 14, 2023
Abstract
Alzheimer’s
disease
(AD)
is
a
common
age-related
neurodegenerative
in
the
central
nervous
system
and
primary
cause
of
dementia.
It
clinically
characterized
by
memory
impairment,
aphasia,
apraxia,
agnosia,
visuospatial
executive
dysfunction,
behavioral
changes,
so
on.
Incidence
this
was
bound
up
with
age,
genetic
factors,
cardiovascular
cerebrovascular
other
basic
diseases,
but
exact
etiology
has
not
been
clarified.
MicroRNAs
(miRNAs)
are
small
endogenous
non-coding
RNAs
that
were
involved
regulation
post-transcriptional
gene
expression.
miRNAs
have
extensively
studied
as
noninvasive
potential
biomarkers
for
due
to
their
relative
stability
bodily
fluids.
In
addition,
they
play
significant
role
physiological
pathological
processes
various
neurological
disorders,
including
stroke,
AD,
Parkinson’s
disease.
MiR-155,
an
important
pro-inflammatory
mediator
neuroinflammation,
reported
participate
progression
β-amyloid
peptide
tau
via
regulating
immunity
inflammation.
review,
we
put
emphasis
on
effects
miR-155
AD
explore
underlying
biological
mechanisms
which
could
provide
novel
approach
diagnosis
treatment
AD.
Frontiers in Aging Neuroscience,
Год журнала:
2022,
Номер
14
Опубликована: Сен. 7, 2022
Alzheimer’s
disease
(AD)
is
a
neurodegenerative
disorder
that
causes
progressive
loss
of
cognitive
functions
like
thinking,
memory,
reasoning,
behavioral
abilities,
and
social
skills
thus
affecting
the
ability
person
to
perform
normal
daily
independently.
There
no
definitive
cure
for
this
disease,
treatment
options
available
management
are
not
very
effective
as
well.
Based
on
histopathology,
AD
characterized
by
accumulation
insoluble
deposits
amyloid
beta
(Aβ)
plaques
neurofibrillary
tangles
(NFTs).
Although
several
molecular
events
contribute
formation
these
deposits,
aberrant
post-translational
modifications
(PTMs)
AD-related
proteins
(like
APP,
Aβ,
tau,
BACE1)
also
known
be
involved
in
onset
progression
disease.
However,
early
diagnosis
well
development
therapeutic
approaches
impeded
lack
proper
clinical
biomarkers.
In
review,
we
summarized
current
status
relevance
biomarkers
from
cerebrospinal
fluid
(CSF),
blood
extracellular
vesicles
AD.
Moreover,
highlight
effects
PTMs
proteins,
provide
an
insight
how
impact
structure
function
leading
pathology.
Finally,
disease-modifying
therapeutics,
novel
approaches,
targets
discussed
successful
Frontiers in Aging Neuroscience,
Год журнала:
2023,
Номер
15
Опубликована: Сен. 13, 2023
This
systematic
review
and
meta-analysis
was
conducted
to
provide
an
analysis
of
the
published
data
about
effects
cognitive
behavioral
therapies
on
depression
older
adults
with
a
diagnosis
Alzheimer's
disease.This
study
performed
following
PRISMA
2020
guidelines.
The
search
between
March
April
2023,
using
four
electronic
databases:
PubMed,
Web
Science,
Cinhal
Scopus.
Different
keywords
combined
Boolean
operators
were
utilized.
Only
11
articles
included
out
initial
212.Cognitive
therapy
found
reduce
in
individuals
Alzheimer's,
including
treatments
low
frequency
but
longer
intervention
time.This
that
psychosocial
is
effective
improving
Alzheimer's.
However,
results
are
inconclusive
due
disparity
findings
heterogeneity
applied
protocols,
so
more
studies
needed
this
topic.https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=416396,
CRD42023416396.
International Journal of Translational Medicine,
Год журнала:
2022,
Номер
2(3), С. 482 - 505
Опубликована: Сен. 3, 2022
Depression
is
a
prevalent
and
debilitating
disease
worldwide.
This
pathology
very
complex
the
lack
of
efficient
therapeutic
modalities,
as
well
high
rates
relapse,
makes
study
treatment
depression
global
healthcare
challenge.
Thus,
an
intense
investigation
this
crucial
urgent.
In
study,
we
focused
on
hydrogen
peroxide
corticosterone-induced
stress
SH-SY5Y
HT-22
cells.
Additionally,
aimed
to
potential
attenuation
these
induced
with
exposure
both
cells
mirtazapine
L-tryptophan,
focusing
cell
viability
assays
(MTT
Neutral
Red)
reactive
oxygen
species
production
(DCFDA
fluorescence).
Taken
together,
our
results
indicate
that
L-tryptophan
counteract
cellular
by
but
not
corticosterone,
revealing
role
agents
oxidative
relief,
highlighting
serotonergic
pathways
in
present
depressed
individuals.
allows
using
models,
enabling
screening
compounds
may
have
be
used
acting
mechanisms
such
protection.
CPT Pharmacometrics & Systems Pharmacology,
Год журнала:
2023,
Номер
12(8), С. 1119 - 1131
Опубликована: Май 2, 2023
Abstract
Psychotic
symptoms
are
reported
as
one
of
the
most
common
complications
Alzheimer's
disease
(AD),
in
whom
they
associated
with
more
rapid
deterioration
and
increased
mortality.
Empiric
treatments,
namely
first
second‐generation
antipsychotics,
confer
modest
efficacy
patients
AD
psychosis
(AD+P)
themselves
increase
Recent
studies
suggested
use
beneficial
effects
antidepressants
among
AD+P.
This
motivates
our
rationale
for
exploring
their
potential
a
novel
combination
therapy
option
these
patients.
We
included
electronic
medical
records
10,260
study.
Survival
analysis
was
performed
to
assess
antipsychotics
on
mortality
A
protein–protein
interaction
network
representing
AD+P
built,
methods
were
used
quantify
drugs
combined
score
developed
measure
synergetic
effect
against
Our
survival
analyses
showed
that
co‐administration
have
significant
reducing
targets
well‐separated,
similar
Signed
Jaccard
Index
(SJI)
scores
Eight
drug
pairs,
including
some
popular
recommendations
like
aripiprazole/sertraline,
higher
than
average
which
suggest
treating
via
strong
effects.
proposed
combinations
antipsychotic
antidepressant
superiority
over
current
treatment
The
observed
can
be
further
strengthened
by
optimizing
drug‐pair
selection
based
systems
pharmacology
analysis.